Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017, Article ID 3540749, 6 pages
https://doi.org/10.1155/2017/3540749
Research Article

Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost

Department of Ophthalmology, St Marianna University School of Medicine, Kanagawa, Japan

Correspondence should be addressed to Naoto Tokuda; moc.ytfin@oanukot

Received 3 May 2017; Accepted 16 July 2017; Published 2 August 2017

Academic Editor: Usha P. Andley

Copyright © 2017 Naoto Tokuda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Alm and J. Stjernschantz, “Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group,” Ophthalmology, vol. 102, no. 12, pp. 1743–1752, 1995. View at Publisher · View at Google Scholar
  2. M. A. Johnstone, “Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost,” American Journal of Ophthalmology, vol. 124, no. 4, pp. 544–547, 1997. View at Publisher · View at Google Scholar
  3. T. Filippopoulos, J. S. Paula, N. Torun, M. P. Hatton, L. R. Pasquale, and C. L. Grosskreutz, “Periorbital changes associated with topical bimatoprost,” Ophthalmic Plastic and Reconstructive Surgery, vol. 24, no. 4, pp. 302–307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. H. Tsai, E. Derby, E. J. Holland, and A. K. Khatana, “Incidence and prevalence of glaucoma in severe ocular surface disease,” Cornea, vol. 25, no. 5, pp. 530–532, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. C. de Jong, T. Stolwijk, E. Kuppens, R. de Keizer, and J. van Best, “Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 232, no. 4, pp. 221–224, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. G. J. Berdy, M. B. Abelson, L. M. Smith, and M. A. George, “Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects,” Archives of Ophthalmology, vol. 110, no. 4, pp. 528–532, 1992. View at Google Scholar
  7. H. Ichijima, W. M. Petroll, J. V. Jester, and H. D. Cavanagh, “Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride,” Cornea, vol. 11, no. 3, pp. 221–225, 1992. View at Google Scholar
  8. M. J. Doughty, “Acute effects of chlorobutanol- or benzalkonium chloride-containing artificial tears on the surface features of rabbit corneal epithelial cells,” Optometry and Vision Science, vol. 71, no. 9, pp. 562–572, 1994. View at Publisher · View at Google Scholar
  9. F. Becquet, M. Goldschild, M. S. Moldovan, M. Ettaiche, P. Gastaud, and C. Baudouin, “Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface,” Current Eye Research, vol. 17, no. 4, pp. 419–425, 1998. View at Google Scholar
  10. P. J. Pisella, K. Fillacier, P. P. Elena, C. Debbasch, and C. Baudouin, “Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits,” Ophthalmic Research, vol. 32, no. 1, pp. 3–8, 2000. View at Publisher · View at Google Scholar
  11. G. Geerling, J. T. Daniels, J. K. Dart, I. A. Cree, and P. T. Khaw, “Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells,” Investigative Ophthalmology & Visual Science, vol. 42, no. 5, pp. 948–956, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. R. W. Yee, E. G. Norcom, and X. C. Zhao, “Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system,” Advances in Therapy, vol. 23, no. 4, pp. 511–519, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. N. L. Burstein, “The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye,” Transactions of the Ophthalmological Societies of the United Kingdom, vol. 104, Part 4, pp. 402–409, 1985. View at Google Scholar
  14. C. Baudouin, A. Labbé, H. Liang, A. Pauly, and F. Brignole-Baudouin, “Preservatives in eyedrops: the good, the bad and the ugly,” Progress in Retinal and Eye Research, vol. 29, no. 4, pp. 312–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Y. Kahook and R. J. Noecker, “Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears,” Cornea, vol. 27, no. 3, pp. 339–343, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Q. Dong, D. M. Babusis, D. F. Welty, A. A. Acheampong, D. Tang-Liu, and S. M. Whitcup, “Effects of the preservative Purite® on the bioavailability of Brimonidine in the aqueous humor of rabbits,” Journal of Ocular Pharmacology and Therapeutics, vol. 20, no. 4, pp. 285–292, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. “The Japan glaucoma society guidelines for glaucoma (3rd edition),” Nippon Ganka Gakkai Zasshi, vol. 116, no. 1, pp. 3–46, 2012, Japanese.
  18. N. Yokoi and S. Kinoshita, “Clinical evaluation of corneal epithelial barrier function with the slit-lamp fluorophotometer,” Cornea, vol. 14, no. 4, pp. 485–489, 1995. View at Google Scholar
  19. T. Ishibashi, N. Yokoi, and S. Kinoshita, “Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride,” Journal of Glaucoma, vol. 12, no. 6, pp. 486–490, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. S. Norn, “Desiccation of the precorneal tear film, corneal wetting time,” Acta Ophthalmologica Scandinavica, vol. 47, no. 4, pp. 865–880, 1969. View at Google Scholar
  21. K. Miyata, S. Amano, M. Sawa, and T. Nishida, “A novel grading method for superficial punctate keratopathy magnitude and correction with corneal epithelial permeability,” Archives of Ophthalmology, vol. 121, no. 11, pp. 1537–1539, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. C. E. Traverso, A. Ropo, M. Papadia, and H. Uusitalo, “A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost,” Journal of Ocular Pharmacology and Therapeutics, vol. 26, no. 1, pp. 97–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Uusitalo, L. E. Pillunat, and A. Ropo, “Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular. Hypertension: 24-month results of a randomized, double-masked phase III study; phase III study investigators,” Acta Ophthalmologica, vol. 88, no. 1, pp. 12–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Uusitalo, E. Chen, N. Pfeiffer et al., “Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication,” Acta Ophthalmologica, vol. 88, no. 3, pp. 329–336, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Hommer and F. Kimmich, “Switching patients from preserved prostaglandin-analog monotherapy top preservative-free tafluprost,” Clinical Ophthalmology, vol. 5, pp. 623–631, 2011. View at Publisher · View at Google Scholar
  26. T. Hamacher, J. Airaksinen, V. Saarela, M. J. Liinamaa, U. Richter, and A. Ropo, “Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis,” Acta Ophthalmologica, vol. 242, pp. 14–19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Ishibashi, N. Yokoi, M. Ohtsuki, K. Mori, A. Komuro, and S. Kinoshita, “Influence of latanoprost on the corneal epithelial barrier function in glaucoma patients,” Ophthalmologica, vol. 216, no. 5, pp. 351–354, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Goto, N. Ibaraki, and K. Miyake, “Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol,” Archives of Ophthalmology, vol. 121, no. 6, pp. 835–839, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Nakagawa, T. Usui, S. Yokoo et al., “Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets,” Investigative Ophthalmology & Visual Science, vol. 3, no. 53, pp. 5154–5160, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Terai, M. Muller-Holz, E. Spoerl, and L. E. Pillunat, “Short-term effect of topical antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy subjects,” Clinical Ophthalmology, vol. 5, pp. 517–525, 2011. View at Publisher · View at Google Scholar · View at Scopus